13FGuru
Sign in with Google Sign in with Discord

None · None

Praxis Precision Medicines, Inc. PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.

Sources StockAnalysis company profile stockanalysis.com

Company profile

Business mix

  • The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
  • It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor.
  • In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1.
  • It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 3.2% $564.9M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 3 13F filing periods
Net reducers 0 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $342.7M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +154.3% +1,063,710 / 689,488
Baker Bros. Advisors 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 63.4% 13F value change +$295.5M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 55.6% 13F value change +$232.8M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 689,488 Last 3 periods +1,063,710 (+154.3%) Total shares 1,753,198 Value $564.9M

Recent mentions

No public mentions.